Crinecerfont
A medication that blocks the corticotropin-releasing factor receptor, reducing the production of adrenal androgens in patients with congenital adrenal hyperplasia. It helps normalize hormone levels and may reduce the need for high doses of corticosteroids.
Peso Molecular
483,0000 g/mol
LogP
8,00
TPSA
53,60 Ų
Regra dos 5 de Lipinski
Aprovado
Mecanismo de Ação
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
C#CCN(c1nc(-c2cc(C)c(OC)cc2Cl)c(C)s1)[C@@H](CC1CC1)c1ccc(C)c(F)c1
InChI
InChI=1S/C27H28ClFN2OS/c1-6-11-31(24(13-19-8-9-19)20-10-7-16(2)23(29)14-20)27-30-26(18(4)33-27)21-12-17(3)25(32-5)15-22(21)28/h1,7,10,12,14-15,19,24H,8-9,11,13H2,2-5H3/t24-/m0/s1
Molecular Formula
C27H28ClFN2OS
HBD / HBA
- / 5
Ligações Rotacionáveis
8
Átomos Pesados
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A medication that blocks the corticotropin-releasing factor receptor, reducing the production of adrenal androgens in patients with congenital adrenal hyperplasia. It helps normalize hormone levels and may reduce the need for high doses of corticosteroids.
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.
Yes, Crinecerfont is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL291657. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5282340. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="crinecerfont"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/crinecerfont/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/crinecerfont/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/crinecerfont/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="crinecerfont"></drugfyi-drug>